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ABSTRACT
Background.  Previous epidemiological and experimental studies indicated cholesterol 
as a central player  in Alzheimer disease (AD).  Here, we utilized skin fibroblasts and 
PBMC  as  possible  ex  vivo  models  for  the  study  of  dysfunctions  of  cholesterol 
homeostasis which may be related to AD development. 
Methods. We  analyzed  cholesterol  homeostasis  using  colorimetric,  thin  layer 
chromatography (TLC), and histologic technique in ex vivo cultures of skin fibroblasts 
and  PBMCs  from  patients  with  probable  AD  and  their  first-degree  relatives. 
Additionally, healthy age-matched individuals served as controls. 
Findings.  As compared  to controls,  skin fibroblasts  and PBMCs from AD patients, 
displayed  an  evident  alteration  of  cholesterol  metabolism;  namely  an  anomalous 
accumulation of cholesterol esters in their cytoplasm. No change in intracellular free 
cholesterol was observed. Cellular overloading of cholesterol esters was dramatically 
increased after specific growth stimulation of the different cell types. Cholesterol ester 
accumulation was negatively correlated  to plasma levels  of  high density  lipoprotein 
cholesterol  (HDL-C)  and  positively  correlated  with  severity  of  cognitive  symptoms 
measured  by  Mini-Mental  State  Examination  (MMSE).  Inhibitors  of   cholesterol 
esterification,  such  as  progesterone  and SaH,  as  well  as  a  potent  inhibitor  of   cell 
proliferation, RAD, were able to prevent accumulation of cholesterol esters. 
Interpretation. Changes of cholesterol esters  in the peripheral compartment  may be 
indicative of a systemic alteration of intracellular cholesterol homeostasis, which in turn 
might create a cellular milieu favourable to the production of ß-amyloid in the brain. 
Pathways that control cholesterol esterification might represent promising targets for 
novel diagnostic and therapeutic AD approaches.
INTRODUCTION
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive 
deterioration  of  memory  and  cognition.  Neural  damage  is  thought  to  result  from 
deposition of -amyloid peptide (A ), a low molecular weight fragment derived fromβ β  
the amyloid precursor protein (APP) after  proteolytic cleavage by the -secretases.β  1,2 
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and  3
.  Many studies over  the last  decade have provided a mass of information about 
structural  and  biochemical  co-factors  favouring  A  deposition  in  AD  patients.β 4 
Particular  attention has  been  devoted  to  changes  in  cholesterol  metabolism.5,  6,7  and  8 
However,  these studies carried out in animal models or in cell culture systems have 
often yielded conflicting results.   Several  “in vitro” studies have reported a reduced 
secretion of A  in cells that have been depleted of cholesterol β 4,6,9  . In line with these 
findings some, “in vivo” studies have shown that an environment low in cholesterol 
favours the production of the non-amyloidogenic, soluble fragments of  ( APPs).α 9,10 
On the basis of such findings it has been suggested that an high cholesterol content in 
rafts, where -secretases are located, could promote the co-clustering of these enzymesβ  
and APP, thereby promoting the production of APP-derived  amyloidogenic cleavage 
fragments.  However,  contrasting  with this  picture,   some “in vivo” evidence would 
indicate  that  low   brain  cholesterol  levels  can  in  fact  promote  AD  development.11 
Moreover,  some  clinical  evidence  does  not  support  the  notion  that  high  brain 
cholesterol levels are associate with AD development. In fact, a reduction rather than an 
increase in membrane cholesterol was  observed in  the hippocampus of  AD patients by 
Ledesma and collaborators12, while  Abad-Rodriguez and collaborators,13 demonstrated 
that a reduction of membrane cholesterol  in hippocampal  neurons from AD patients 
resulted in a higher ß-secretase –APP co-localization in rafts associated with an elevated 
production of A . Since a comprehensive view of the complex relationship betweenβ  
cholesterol metabolism and AD is still lacking, it is difficult, at present, to reconcile all 
these conflicting reports. However, it is reasonable to suggest that, similarly to other 
metabolic and biochemical alterations found in AD patients, alterations in cholesterol 
metabolism, rather than being confined to the brain tissue, might be systemic in AD 
patients.  Indeed, a  number  of  abnormalities  in metabolic  and biochemical  processes 
described in AD brains have also been found in cultured skin fibroblasts derived from 
AD patients, 14,15 thus supporting the view that AD might be seen as a systemic disorder 
and that fibroblasts and other peripheral cells might be useful to identify and to test 
hypotheses  on  brain  pathological  mechanisms  leading  to  AD.  Starting  from  these 
considerations,  in  the  present  work  we  investigated  cholesterol  metabolism in  skin 
fibroblasts and in peripheral blood mononuclear cells (PBMCs)  from AD patients and 
their first-degree relatives as possible ex vivo models for the identification of alterations 
in  cholesterol  homeostatic  regulatory  pathways  that  may  be  relevant  to  AD 
development and progression. 
METHODS
Participants. In a first phase of study, we took advantage of a pre-existing bank of skin 
fibroblasts collected as part of a project of "Ricerca Finalizzata Alzheimer", funded  by 
the Ministero  della  Salute  through Regione Toscana and entitled "Identification and 
validation of peripheral markers of altered proteolysis in AD patients.  All individuals 
included in this  study were  enrolled at  the  Azienda USL 4,  Geriatric  Unit  of Prato 
Hospital  (Italy).  The  dermal  biopsies  were  obtained,  following  informed  written 
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consent, from the upper forearm of the subjects by a 2-mm punch after local anesthesia 
with 2% xylocaine, according to the  guidelines established and approved by the local 
Ethical Committee of Azienda USL 4, Prato (Italy). We analysed fibroblasts from six 
non-AD controls (six females, mean age 67.0 ± 6.1 years) and seven AD patients (five 
females, two males, mean age 73.8 ± 9.4 years). In a second phase, blood samples were 
obtained from 62 patients with probable AD (range: 64–91 years; mean ± S.E. = 78.6 ± 
0.8), predominantly women (49/62) and from 78 first-degree relatives (range:  26-87 
years; mean ± S.E = 47.0  ± 1.3) (55/78 women), recruited at the Geriatric Service of 
Alzheimer Center, USL 8, Cagliari (Italy). Informed written consent was obtained from 
all the subjects or, when necessary, from their legal guardians under local institutional 
review board supervision and approval (# 351, 14 Feb 2003) of local Ethical Committee 
of USL 8, Cagliari, Italy. Routine clinical and laboratory evaluation, including magnetic 
resonance imaging, was performed to exclude other causes of cognitive impairment. 
The Reisberg Global Deterioration Scale (GDS) was used to indicate the severity of the 
cognitive  impairment  in  AD patients.  Abnormal  GDS levels  start  from level  3  and 
maximal deterioration grade corresponds to level 7. Patient evaluation included medical 
history,  physical  and  neurological  examinations,  laboratory  blood  tests  to  rule  out 
metabolic  causes  of  dementia  (thyroid  hormones,  Vitamin  B12,  and  erythrocyte 
sedimentation  rate),  and  a  neuroimaging   (computed  tomography  and/or  magnetic 
resonance)  of  the  brain.   In  addition,  all  patients  received  neuropsychological  tests 
including  the  Mini-Mental  State  Examination  (MMSE)  (mean  ±S.E.  =  18.9±0.5). 
Patients with neoplastic or hematological disorders, recent infections or surgery, severe 
hepatic  or  renal  failure,  myocardial  infarction  or  cranial  trauma  in  the  previous  6 
months,  or  who  had  received  statins,  antineoplastic,  corticosteroid,  or 
immunosuppressive  drug  treatments  were  not  included  in  the  present  study. 
Additionally, 114 individuals: 30 volunteers aged between 65-87 years (22/30 women) 
with  no cognitive impairment, as determined by clinical interview and by a normal 
MMSE score (29.4 ± 0.6) and 84 blood donors, recruited at the Centro Trasfusionale, 
USL7,  Iglesias,  Italy,  (35/84  women)  aged  between  19  and  69  years; 
mean±S.E.=42.5±1.3, with no personal or family history of neurological or psychiatric 
disorders, served as controls.
Cell  cultures.  Skin  fibroblasts  were  isolated  by  dermal  biopsies  obtained  from the 
upper  forearm by a 2-mm punch after  local anesthesia with 2% xylocaine.  Biopsies 
were washed with sterile PBS supplemented with penicillin and streptomycin, minced 
to pieces,  transferred  to culture  dishes and overlaid with a coverslip.  Cultures  were 
incubated at 37°C in 5% CO2  humidified atmosphere with DMEM containing 4.5 g/l 
glucose and 10% FCS for  18-21 days  to  obtain primary  cultures  of  human diploid 
fibroblasts.  These  were   then  subcultured, seeded  onto  60-mm  plastic  Petri  dishes 
(28 cm2)  in  10%  FCS–DMEM  and  grown  to  confluence   All  experiments  were 
completed using fibroblasts between passages two to three in culture.  For “in vitro” 
kinetic experiments, cells were plated at a density of 10.000 cell/cm2 in 6 well plates 
and  then  incubated  for  48  h  in  DMEM with  0.2%  FCS to  synchronize  cells  at  a 
quiescent state.  Quiescent fibroblasts  were then diluted in complete growth medium 
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with  10%  FCS,  either  in  the  presence  or  in  the  absence  of  20  nM  of  40-O-(2-
hydroxyethyl)  rapamycin  (RAD)  (supplied  by  Novartis  Pharma  AG,  Basel, 
Switzerland). In addition, 10 µM of Progesterone (PG)  (Sigma-Aldrich, St. Louis, MO) 
and 4  µM of the acyl amide ACAT inhibitor SaH (Novartis Pharma AG, Basel) was 
added  to  some  cultures   as  a  broad-spectrum  regulators of  cholesterol  ester  cycle. 
Preliminary experiments were carried out to find the minimal effective dosages with the 
least  effect  on  cell  viability.  Cells  were  harvested  at  indicated  time  points  after 
treatments.  Cell  proliferation  was  assessed  by  direct  cell  counting  with  a 
hemocytometer. The trypan blue exclusion test was used to assess cell viability.
Blood samples.  Blood samples were centrifuged at 2200 rpm for 15 min to separate 
plasma. Plasma was removed, transferred to centrifuge tubes and stored at –80C° until 
analyses.  The  buffy  coat  was  collected  and the  peripheral  blood mononuclear  cells 
(  PBMCs  )  were  isolated  by  density-gradient  centrifugation  (Lymphoprep;  density, 
1.077 g/L; Nycomed Pharma, Oslo, Norway) at 1200 rpm for 10 minutes at 20°C, and 
washed twice with Hanks balanced salt solution (HBSS). Purified PBMCs were then 
seeded onto 24-well plates at 1.0 × 106/mL in RPMI 1640 medium with the standard 
supplements:  (10%  fetal  calf  serum  (FCS),  200  mM  L-glutamine,  and  100  U/mL 
penicillin-streptomycin)  and,  where  indicated,  growth-stimulated  with  10  µg/ml 
phytohemagglutinin (PHA; Sigma) in the presence or in the absence of 20 nM of RAD. 
Plasma lipid profile.Total (TC) and HDL cholesterol (HDL-C) content was determined 
in  plasma  by  routine  colorimetric  enzymatic  procedures  (Sclavo  Diagnostics 
International S.r.l. Sovicille, Italy).
Cholesterol  esterification  and  lipid  cell  content.  Cholesterol  esterification  was 
evaluated  by  incubating  cells  for  6  hours  in  medium  containing  [1-14C]oleic  acid 
(Dupont,  NEN  55  mCi/mmol),  bound  to  bovine  serum  albumin  (BSA)  at  a  final 
concentration of 2  µCi/ml.  After  incubation cells were  washed with PBS and lipids 
extracted with acetone. Lipid subclasses were separated by thin layer chromatography 
(TLC ) and incorporation of [14C]oleate into cholesterol esters was measured. For lipid 
cell content determinations, free  (FC) and esterified cholesterol (CE) were separated by 
TLC and their mass determined by enzymatic assay methods.
Neutral  lipid  staining.  To  visualize  the  degree  of  cytoplasmic   neutral  lipid 
accumulation, cultured fibroblasts and freshly isolated PBMCs were washed three times 
with PBS and fixed by soaking in 10% formalin. Cells were then treated with isopropyl 
alcohol (60%), washed, stained with oil red O (ORO) (a lipid-soluble dye that stains 
cholesterol  esters  but  not  free  cholesterol)  and  counterstained  with  Mayer’s 
hematoxylin. Stained cells were examined by light microscopy and digital images were 
recorded. For quantification of mean neutral lipid content in skin fibroblasts,  red color 
intensity was measured in single cells using the software Scion Image (Scion Corp., 
Fredrick, Maryland, USA). Values were expressed as the mean of  red color intensity in 
each  cell,  determined  in  at  least  30  single  cells  in  six  random  microscopic  fields. 
Neutral  lipids in ORO stained PBMCs calculated as above were further graded into 5 
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classes:  0  (0),  1  (+),  2  (++),  3  (+++) and 4 (++++) based on mean color  intensity 
measurements.
Statistical  analysis.  Data  are  reported  as  mean  ±  standard  error  (SE).  Statistical 
calculations were performed using the statistical analysis software of Origin 7.0 version 
(Microcal,  Inc,  Northampton,  MA, USA).  A value  of  P<0.05 was considered  to  be 
statistically significant.  Correlation  analysis  were  performed  by  correlation  test of 
Microsoft Excel for Statistics. 
Funding  source.  This  study  was  supported  by  grants  of  Regione  Autonoma  della 
Sardegna and of Monte dei Paschi di Siena.
RESULTS
A number of abnormalities in metabolic and biochemical processes described in AD 
brains  have  been  found  in  cultured  skin  fibroblasts  derived  from  AD  patients.14,15 
Prompted  by  our  previous  findings  of  a  tight  correlation  between  cell  growth  and 
cholesterol  ester  accumulation16,17,18  and  20 in  various  cell  systems  and  by  studies 
demonstrating abnormally high levels of intracellular lipid droplets (mainly cholesterol 
esters) in cell-based and animal models of AD 21, 22, 23, and 24, we initially sought to explore 
a  possible  relationship  between  growth  capability  and  the  extent  of  cholesterol 
esterification in skin fibroblasts obtained from AD patients (AD fibroblasts). Direct cell 
counting  revealed  a  significantly  higher  mytogenic  response  of  AD  fibroblasts  as 
compared to control fibroblasts 72 hours after 10% FCS stimulation (5x106  vs. 3x106 
cells/ml). As expected, the increase in cell number correlated with a parallel increase in 
the rate of cholesterol esterification (data not shown). Noteworthy, total cholesterol was 
significantly  higher  in  AD  fibroblasts  as  compared  to  controls  (59,3  ± 2.0  µg 
cholesterol/mg  cell  protein  vs.  45.0  ± 1.5  µg  cholesterol/mg  cell  protein  );  this 
increment was mainly accounted by an increased CE content in AD fibroblasts  and 
resulted in a striking decrease in the FC /CE  ratio in these cells (2.5 ± 0 3, vs 11.2 ± 
1.2). Analysis by ORO staining revealed that unstimulated control fibroblasts contain 
very low basal levels of cytoplasmic neutral lipid droplets (figure 1), confirming that, 
under normal conditions, intracellular cholesterol esters are maintained at low levels, 
possibly  by  a  cyclic  process of  de-esterification  and  re-esterification,  as  originally 
suggested  by  Goldstein  and  Brown  25.  On  the  other  hand,  ORO  staining  of  AD-
fibroblasts  confirmed  that  this  regulatory  mechanism  is  altered  in  AD  patients,  as 
evidenced by the greatly expanded cytoplasmic CE pool in these cells (figure 1 A and 
B).  Moreover,  the finding that,  three different  inhibitors  of cholesterol  esterification 
were able to reduce lipid droplet accumulation in AD fibroblasts (figure 1B) constitutes 
a strong evidence that this expanded CE pool is, at least partly,  due to an  increased 
esterification  activity.  Taken  together,  these  results  suggest  that  the  mechanism(s) 
involved in the regulation of cholesterol esterification may be systemically altered in 
AD-patients. 
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Figure 1.  Neutral lipids in fibroblasts from controls and AD patients. The upper panel (A) 
shows analysis of ORO-stainings performed on six controls and seven AD different fibroblast 
cell cultures. Bars indicate the mean ± SE of red color intensity/cell, determined in each culture 
well in at least 30 single cells in six random microscopic fields.  *p < 0.05 vs. control values. 
Panel B shows lipid droplet accumulation in 48 hours FCS stimulated AD fibroblasts incubated 
in the presence or in the absence of SaH. PG, and  RAD. Shown are results from 1 control and 1 
AD patient which are representative of six controls and seven AD different fibroblast cell lines.
If this hypothesis is correct, than at least in theory, one should expect that this systemic 
alteration could also be reflected by changes of lipid levels in the plasma. To test such a 
possibility we thus studied TC and HDL-C levels in plasma and neutral lipid content in 
PBMCs from 62 patients with probable AD as well as from  30 age-matched healthy 
controls. Levels of TC were moderately decreased in the plasma from AD patients as 
compared to controls but this was not statistically significant. By contrast, plasma HDL-
C levels were significantly decreased, in AD patients 
(figure 2A) as compared to controls. This paralleled with increased levels of CE  in AD-
PBMCs (figure  2B) indicating that  abnormally low levels  of  HDL-C coupled with 
cytoplasmic accumulation of CE might be relevant in AD pathogenesis. 
If examined individually,  the majority of AD-PBMCs (53%) had ORO staining levels 
(calculated as stated in Methods)  that scored between 3 and 4, while the majority of 
PBMCs  from  controls  (58  %)  scored  between   0  and  1  (figure  3A).  In  addition, 
correlation  test  revealed  that  in  AD patients,  ORO staining  levels in  PBMCs were 
negatively correlated with HDL-C levels in plasma (r=-0.44, P< 0.05) (figure 3B).
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Although the significance, if any, of observed correlation  between low HDL-C levels 
and AD risk remains to be established, the data presented above lead to suggest that the 
low HDL-C levels in the plasma of AD patients may be a consequence of a decreased 
removal rate of cholesterol from tissues, possibly as a result of the increased rate of 
cholesterol esterification and intracellular lipid droplet accumulation. Interestingly,  the 
intensity of ORO staining in PBMCs of AD was significantly and directly correlated 
with the severity of cognitive alteration, determined by the MMSE scores (r = -0.41; 
p < 0.05) (figure 3 C). This last finding would suggest that, rather than being just an 
epiphenomenon, this  metabolic  alteration might  have some clinical relevance  and/or 
perhaps contribute to the pathogenesis of this disease.
Figure 2. Plasma cholesterol and neutral lipids in PBMCs  from AD patients (AD-PBMCs). 
Panel A shows TC and HDL-C in plasma of  62 AD patients and  30 age-matched controls. 
*P<0.05 vs controls.  Panel B shows neutral lipid droplet accumulation as determined by ORO 
method in quiescent (0h) and 48 hours PHA stimulated AD-PBMCs incubated in the presence 
or in the absence of RAD.
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Figure 3. Correlation between neutral lipid in PBMCs and HDL-C levels in plasma. Panel A. 
Numbers of control and AD blood samples, distributed according to the intensity of the ORO 
bound lipids, and sub-divided  into five classes:  (0), 1(+), 2 (++), 3 (+++) and 4 (++++) based 
on intensity measurements.  Panel B Correlations between HDL-C and ORO intensity in AD 
and age-matched controls.  Panel C Correlations between MMSE scores and ORO intensity in 
AD and age-matched controls. 
It is well known that individuals who have had a late onset-AD case in their family may 
run an increased risk of developing AD themselves.26  However, with the exception of 
apolipoprotein  E  polymorphisms,27  and  28  no accepted  indicator  is  so  far  available  to 
estimate  risk   in  AD relatives. It  will  be  thus  worth  investigating  whether  altered 
cholesterol metabolic profile might serve for the pre-clinical identification of  a subset 
of AD relatives who might be at major risk of developing  AD later in their lifetime. We 
therefore  studied HDL-C levels  in plasma and the content of ORO lipid droplets  in 
PBMCs in 78 first-degree relatives of AD patients and compared the data with those 
obtained from 84 age-matched healthy controls. When compared to both the AD and 
control groups, a greater variability was observed in the data obtained from first-degree 
AD relatives (mean age: 47.0  ± 1.3), and a partial overlap was present with the data 
from a control group (mean age: 42. 5± 1.3) (figure 4A). However, 41% of PBMCs 
from AD relatives had ORO staining levels that scored between 2 and 3, as compared to 
only 18% of PBMCs from controls (Figure 4B). 
Figure 4.  Correlation between neutral lipid in PBMCs and HDL-C levels in plasma of first 
degree relatives of AD patients. Panel A. Total and HDL-C levels. Panel B. Numbers of control 
and AD first degree relatives blood samples, distributed according to the intensity of the ORO 
bound lipids, and sub-divided  into five classes:  (0), 1(+), 2 (++), 3 (+++) and 4 (++++) based 
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on intensity measurements.  Panel C. Correlations between HDL-C and ORO intensity in AD 
first degree relatives and age-matched controls.
In addition,  similarly  to  what  observed  in  AD patients,  plasma HDL-C levels  were 
significantly correlated with ORO intensity  (r=-0.39,  P< 0.05) in  AD relatives  (figure 
4C), indicating that some AD relatives tend to display a cholesterol metabolic pattern 
similar  to  that  of  typical  AD patients.  Interestingly,  three  unaffected  relatives  (two 
brothers and 1 sister) of comparable age of three AD patients did not show relevant 
accumulation of neutral lipid in their PBMCs (figure 5). 
Figure  5. Comparison  of  ORO  staining  between  three  AD  patients  and  three  unaffected 
relatives (two brothers and 1 sister) of comparable age.
DISCUSSION
Many experimental and clinical studies indicate that cholesterol plays a role in AD1,5, 23. 
The exact nature of this role, however, remains elusive, since available data are often 
conflicting and in most studies no  information on intracellular cholesterol pools (free 
vs. esterified) and/or lipoprotein fractions was available. High levels of total plasma 
cholesterol have been variably associated with either increased 7,29.30 and 31  or decreased29 
risk of AD, while other studies have found no association at all. Early work that served 
as a rationale for the  use of statins as novel “quick and easy” therapy for AD32, had to 
be  entirely  re-examined  when  three   independent  prospective  studies,  altogether 
accounting for about 30,000 person-years at risk for AD, found no protective effect of 
statins against AD development. The rationale to the use of statins in AD was based on 
the hypothesis that high cholesterol levels accelerate the production of ß-amyloid by 
shifting  APP  metabolism  from  alpha  to  beta  cleavage  products.  According  to  this 
hypothesis, statins, blocking cholesterol synthesis, would cause a reduction in neuronal 
membrane free-cholesterol content, thus inhibiting the activity of  β-secretases. While 
this theoretical  arguments were initially supported by some in vitro observations,   a 
recent epidemiological study found that statins use was associated with a greater risk of 
AD.  33 To explain this surprising result, the authors of this study have suggested  that 
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statins  might  exacerbate  AD  progression  by  inhibiting  cholesterol  synthesis  at  the 
neuronal  level,  thus  altering  cholesterol-dependent  synaptic  integrity and 
neurotransmission.  In  an  attempt  to  understand  the  reasons  for  these  apparently 
conflicting reports and to have a larger view of the relationship between cholesterol and 
AD,  in  the  present  study  we  investigated  and  compared  the  overall  cholesterol 
metabolism  in  patients  with  probable  AD  and  age-matched  healthy  controls.  We 
evaluated lipid profiles in the plasma compartment as well as intracellular cholesterol 
pools in skin fibroblasts and/or PBMCs. Unlike fibroblasts and PBMCs from controls, 
which were virtually devoid of lipid droplets, cells  from AD patients accumulated a 
large  number  of  lipid  droplets  (mainly  cholesterol  esters).  This  accumulation  was 
associated with lower levels of plasma HDL-C, while no change in plasma TC levels 
was observed between AD patients and age-matched controls.  Interestingly, the extent 
of neutral lipid accumulation in cells was inversely correlated  with HDL-C levels in 
plasma. The combination of low plasma HDL–C  and cellular  lipid accumulation is 
intriguing  in  the  light  of  the  proposed  role  of  HDL in  unloading  cholesterol  from 
tissues, including brain, and transporting it back to the liver In this respect, low HDL-C 
levels would seem to indicate  that lipid export from cells is defective in AD patients, 
possibly leading to increased amounts of cholesterol ester storage in the cytoplasm. This 
view is  corroborated  by  studies  showing  that  HDL-C  and  ApoA-I  (the  main 
apolipoprotein of HDL) levels, are significantly lower in the plasma of AD patients in 
comparison to the controls  34,35  and that deficiency in ATP-binding cassette ABCA136, 
the major regulator of cholesterol efflux, increases β-amyloid deposition. Low HDL-C 
levels in plasma and a reduction of LDL receptor expression in PBMC were also found 
in Down syndrome patients which, in spite of high risk for AD, show a low prevalence 
of coronary artery disease.37 
In the present study we found that skin fibroblasts from AD patients, although showing 
a  normal  content  of   free  cholesterol,  display  an  evident  alteration  of  cholesterol 
metabolism;  namely  an  anomalous  accumulation  of  cholesterol  esters  in  their 
cytoplasm.  This  intracellular  overloading  with  cholesterol  esters  was  dramatically 
increased  after  mitogenic  stimulation,  while  two different  inhibitors  of   cholesterol 
esterification,  such  as  progesterone  and SaH,  as  well  as  a  potent  inhibitor  of   cell 
proliferation, RAD, were able to prevent it. We hypothesize that these observed changes 
in cholesterol  esters  in the peripheral  compartment  may be indicative of a  systemic 
alteration of intracellular cholesterol homeostasis, which in turn might create a cellular 
milieu favourable to the production of ß-amyloid in the brain.
In agreement with this hypothesis, Kovacs et al. found that cholesterol-ester levels are 
directly correlated to Aβ production: a decrease in the content of lipid droplets led to a 
decrease in the production of A , whereas abnormally high levels of lipid droplets ledβ  
to an increase in amyloid beta production.  21,24  The Authors   also showed that drugs 
known to inhibit the activity of acyl-coenzyme A:cholesterol acyltransferase (ACAT), 
the enzyme that catalyses the formation of cholesterol esters, are potent modulators of A
β generation21,24.  Moreover,  a  RNAi-induced,  50%  reduction  of  ACAT  expression 
resulted  in  a  significant  suppression  of  A  production  (β 40%)  confirming  that 
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reduction of cellular ACAT activity represents a realistic and specific approach for  the 
modulation A  generation. Therefore, β inhibitors of this enzyme may turn out to be an 
extremely important tool  in the treatment of  AD.22 
Another interesting finding of our study was that neutral lipid accumulation in PBMCs 
correlated  positively  with the  severity  of  dementia,  expressed  by  the  MMSE score. 
These  observations  not  only  indicate  that  a  progressive  systemic  alteration  in 
cholesterol  metabolism  accompanies  the  development  of  mental  deterioration,  thus 
implying measurements of neutral  lipids in peripheral cells, together with HDL-C in 
plasma,  may be useful  in  the monitoring  of AD progression,  but  also suggests  that 
assessment  of  cholesterol  metabolisms  in  peripheral  cells  among  asymptomatic  AD 
relatives might serve to identify those that carry a higher  risk of developing the disease 
at older ages. To our knowledge, these findings are the first ex vivo demonstration that 
alterations of cholesterol metabolism, which are associated with AD and parallel disease 
severity, are also present in peripheral cells, and support biochemical, epidemiological, 
and genetic literature arguing for a deep link between cholesterol and AD. 1,5, 23 Focusing 
on the relationship between cholesterol and APP metabolism would be important for 
etiological as well as for therapeutic purposes, as it might help to understand whether 
early pharmacological interventions on cholesterol levels could provide a relatively safe 
mean to reduce A  accumulation both in brain and in endothelial compartment. Theseβ  
data confirm that new therapeutic approaches targeting lipid metabolism may be useful 
to slow down AD progression. 
In summary, further studies are necessary to elucidate the mechanisms responsible for 
the  alterations  of  cholesterol  homeostasis  in  AD  patients  and  in  their  first  degree 
relatives, and to unveil possible cause-effect relationships between APP cleavage and 
these alterations.  Similarly,  additional  work  is  needed to  fully  explore  the potential 
implication of this association for AD susceptibility. Nonetheless, the data reported in 
the present  paper suggest that accumulation of cholesterol  esters  in peripheral  cells, 
together with a decrease of HDL-C in the plasma might serve to identify a distinctive 
profile  associated with increased susceptibility to AD. In addition,  the lack of an AD 
diagnostic has limited so far the development of specific drugs and the assessment of 
the response  of  peripheral  tissues  to  disease-modifying therapies.  Fibroblasts  and/or 
PBMCs from AD patients could represent an excellent in vitro model to test the toxicity 
as  well  as  the  efficacy  of  agents  capable  of  restoring  the  control  of  cholesterol 
homeostasis toward the profile of the normal phenotype.
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